Germany - Drugs

For more information and to make a bid you will need to go to the third party website.

Details

Provided by Open Opps
Opportunity closing date
05 December 2022
Opportunity publication date
21 December 2020
Category
33600000: Ph
Value of contract
£0-100k
Your guide to exporting
Report opportunity

Description

The purpose of this announcement is to conclude agreements with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 SGB V. The invitation to participate is only addressed to pharmaceutical companies or associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act. It is not an open procedure pursuant to Section 15 VgV in conjunction with Section 119 (3) GWB, but a publication of the invitation to conclude/join rebate contracts with terms and conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act may become contracting parties.
The purpose of this announcement is to conclude agreements on the active ingredient "Imatinib" (ATC code L01XE01)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematic nature of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contracting partners. The information given in section II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or accession is effected by sending the required completed self-declarations or evidence as well as the contract either:a) signed by hand (written form according to § 126 BGB) by post orb) provided with a qualified electronic signature (§ 126a BGB) by e-mail.to openhouse.rabattvertrag2020-12@kbs.de to the CAB.The earliest start of the contract is 1.2.2021, provided that the contract and the required declarations or evidence have been received by the CAB by 5.1.2021 at the latest. The contract thus begins on the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise on the 1st of the month after next. The contract ends automatically, without the need for termination, as soon as contract partners have been determined for the active agent by means of a formal award procedure. The deadline for receipt of accessions is 5.12.2022. In any case, the contract ends on 31.1.2023.

Opportunity closing date
05 December 2022
Value of contract
£0-100k

About the buyer

Address
Deutsche Rentenversicherung Knappschaft-Bahn-See Verwaltungsgebäude Trimonte Park 2/3, Wasserstraße 215 Bochum 44799 Germany
Contact
openhouse.rabattverfahren2020-12@kbs.de

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?